214 related articles for article (PubMed ID: 24428090)
1. CHOEP-21 chemotherapy for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs) in Maharaj Nakorn Chiang Mai Hospital.
Rattarittamrong E; Norasetthada L; Tantiworawit A; Chai-Adisaksopha C; Nawarawong W
J Med Assoc Thai; 2013 Nov; 96(11):1416-22. PubMed ID: 24428090
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
3. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
4. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M
Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124
[TBL] [Abstract][Full Text] [Related]
5. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
Brink M; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer LH; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Plattel W; Huls GA; Vermaat JSP; Nijland M
Blood; 2022 Sep; 140(9):1009-1019. PubMed ID: 35544601
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
Kim JG; Sohn SK; Chae YS; Cho YY; Yang DH; Lee JJ; Kim HJ; Shin HJ; Chung JS; Cho GJ; Lee WS; Joo YD; Sohn CH; Oh SJ
Cancer Chemother Pharmacol; 2007 Jun; 60(1):129-34. PubMed ID: 17406867
[TBL] [Abstract][Full Text] [Related]
7. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
[TBL] [Abstract][Full Text] [Related]
8. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
9. THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
Takamatsu Y; Suzumiya J; Utsunomiya A; Maeda K; Matsuoka H; Suzushima H; Tsukada J; Shibata K; Tamura K;
Eur J Haematol; 2010 May; 84(5):391-7. PubMed ID: 20059527
[TBL] [Abstract][Full Text] [Related]
10. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
[TBL] [Abstract][Full Text] [Related]
13. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
Cederleuf H; Bjerregård Pedersen M; Jerkeman M; Relander T; d'Amore F; Ellin F
Br J Haematol; 2017 Sep; 178(5):739-746. PubMed ID: 28485010
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
[TBL] [Abstract][Full Text] [Related]
15. NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.
Kriachok I; Tytorenko I; Shudrak N; Aleksik O; Stepanishyna Y; Kadnikova T; Pastushenko Y; Shokun N; Rudiyk T; Bushuieva M
Exp Oncol; 2024 Feb; 45(4):474-482. PubMed ID: 38328842
[TBL] [Abstract][Full Text] [Related]
16. Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
Tomita N; Kodama F; Tsuyama N; Sakata S; Takeuchi K; Ishibashi D; Koyama S; Ishii Y; Yamamoto W; Takasaki H; Hagihara M; Kuwabara H; Tanaka M; Hashimoto C; Yamazaki E; Koharazawa H; Fujimaki K; Sakai R; Fujisawa S; Ishigatsubo Y
Hematol Oncol; 2015 Mar; 33(1):9-14. PubMed ID: 24519501
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.
Piccaluga PP; Fuligni F; De Leo A; Bertuzzi C; Rossi M; Bacci F; Sabattini E; Agostinelli C; Gazzola A; Laginestra MA; Mannu C; Sapienza MR; Hartmann S; Hansmann ML; Piva R; Iqbal J; Chan JC; Weisenburger D; Vose JM; Bellei M; Federico M; Inghirami G; Zinzani PL; Pileri SA
J Clin Oncol; 2013 Aug; 31(24):3019-25. PubMed ID: 23857971
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
20. Peripheral T-cell lymphoma with follicular T-cell markers.
Rodríguez-Pinilla SM; Atienza L; Murillo C; Pérez-Rodríguez A; Montes-Moreno S; Roncador G; Pérez-Seoane C; Domínguez P; Camacho FI; Piris MA
Am J Surg Pathol; 2008 Dec; 32(12):1787-99. PubMed ID: 18779728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
